Lithium Supply Takes Years. This Company Isn't Waiting

Most lithium supply still lives in the future.

New projects, new builds, long timelines - 7 to 10 years in many cases. That's the part the market understands.

Demand is moving faster.

EVs, AI, storage - all pulling on the same materials at once. The projections keep getting revised higher, and the gap is starting to show.

That gap creates urgency.

And urgency rewards the companies that move first.

This one did.

Instead of waiting on new supply, it found a way to produce lithium from a source the market largely overlooked - working inside a system that's been running for years, right here in the U.S.

No long buildout. No waiting on new infrastructure.

Just production.

It's early.

But it's already happening.

See who's already producing >

Why Walmart, Target and TJX Got Such Different Reactions After Earnings

Authored by Leo Miller. Article Published: 5/25/2026.

Retail earnings season delivered a clear reminder that good results are not always enough.

Walmart (NASDAQ: WMT), Target (NYSE: TGT) and TJX Companies (NYSE: TJX) all posted solid quarterly numbers recently, but investors reacted to the reports very differently.

Goldman Sachs just told you what to buy (most people missed it) (Ad)

Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up.

One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.

See the stock positioned to solve AI's biggest power crisis

For Walmart and Target, strong sales growth was overshadowed by already elevated expectations and lingering guidance concerns. For TJX, a cleaner setup, stronger outlook and larger buyback plan gave the market a reason to reward the stock.

Walmart: After Its Big Rally, A Strong Quarter Wasn’t Enough

Arguably, the biggest disappointment from the latest round of retail earnings reports was Walmart. Overall, WMT stock dropped 7.3% after it released earnings on May 21.

But the problem wasn’t that Walmart's business wasn't performing well—it most certainly was. The company saw revenue grow by more than 7% year-over-year (YOY), or 5.9% on a constant-currency basis, to $177.75 billion. This marked Walmart's fastest revenue growth since calendar Q1 2023. Adjusted earnings per share (EPS) also rose a solid 8% YOY. Both figures slightly beat Wall Street estimates.

But investors wanted more than a solid quarter. They wanted Walmart to raise its forward expectations as well.

Before its post-earnings decline, Walmart shares had delivered a total return of approximately 25% over the previous six months. That was nearly double the S&P 500’s return of about 13% over the same period.

Walmart, however, maintained its full-year fiscal 2027 outlook. And after the stock’s sharp rally, that decision left investors with little incremental reason to keep bidding shares higher.

Note that the company’s fiscal reporting period is several quarters ahead of the calendar year. The company continues to expect full-year adjusted EPS in the range of $2.75 to $2.85. Additionally, Walmart sees adjusted EPS coming in between 72 cents and 74 cents next quarter—slightly below what analysts had projected.

Target: Returns to Growth, But the Stock Still Lost Ground

Target also received no love from investors after its latest report, with shares falling 3.9% afterward.

Notably, Target has gone on an even more impressive run than Walmart, delivering a total return of over 45% in the last six months.

The company recorded net sales growth of 6.7% YOY, with total revenue rising to $25.44 billion. This ended a five-quarter streak of negative sales growth and marked the company’s highest growth rate since calendar Q4 2021. Adjusted EPS also increased by 32% YOY.

Overall, the company’s sales growth beat estimates moderately, while EPS growth exceeded expectations by a wide margin.

Target even increased its guidance, doubling its net sales growth expectations for the full year from 2% to 4%. It also sees adjusted EPS coming in at the high end of its $7.50 to $8.50 range. However, the company also noted that it is facing tougher comparisons in Q2 and more challenging cost headwinds in the first half of the year. This likely tempered investor enthusiasm around Target’s otherwise strong showing.

Still, Target received support from analysts, many of whom raised their price targets after earnings. The average of targets updated after the report was just under $140, considerably higher than the MarketBeat consensus price target around $125. That updated average target implied upside of around 10% for the shares.

TJX: Gave Investors the Forward Momentum They Wanted

TJX stood out not only for its strong underlying performance, but also for the positive reaction it received from investors.

The company posted revenues of $14.32 billion, an increase of over 9% YOY and TJX’s fastest growth rate in two years. Adjusted EPS rose even faster, climbing 29% YOY to $1.19. Both figures exceeded expectations, with TJX posting a sizable 17-cent bottom-line beat.

TJX also increased its full-year guidance. The company now expects consolidated sales to rise by 5% to 6% YOY, up from its previously forecast growth of 4% to 5% YOY. Pre-tax profit margin guidance also got a boost, moving up to a midpoint estimate of 11.95%, an increase of 20 basis points from prior estimates. Additionally, EPS growth expectations increased to a range of 7% to 9% YOY from 4% to 6% YOY.

It seems investors were likely more willing to reward TJX because the stock had not previously gone on a strong run like the other two names. Before its post-earnings gain, TJX shares were up less than 5% over the past six months. In this case, a lower bar helped, and shares moved up by around 5.6% after the earnings release.

Adding to the positives, TJX announced an increase in its share buyback guidance. This was not a new authorization, but rather TJX telling investors how much it actually plans to spend on buybacks. Overall, the company increased its buyback spending plans by $250 million to between $2.75 billion and $3 billion. After spending $604 million on buybacks during the quarter, this suggests the firm plans to spend around $2.25 billion on buybacks during the rest of the year. That would be equal to approximately 1.3% of its market capitalization.

TJX also received several price target increases after its results. The analyst consensus price target sits around $175, implying about 10% upside from current levels.

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

Authored by Leo Miller. Article Published: 6/2/2026.

After its blockbuster Q1 2026 earnings report, which sent shares up 9.8%, pharmaceutical giant Eli Lilly and Company (NYSE: LLY) continues to stack up wins. These include a Food and Drug Administration (FDA) proposal that would pressure compounders, as well as strong clinical results for its oral GLP-1, Foundayo.

Now, the company is back in the news with a key development that underscores its strong position in the GLP-1 market. Lilly has reached an agreement with CVS Health (NYSE: CVS), the owner of the nation’s largest pharmacy benefit manager (PBM), Caremark. The agreement will expand coverage of Lilly’s top GLP-1s, allowing patients to access them through their existing insurance.

Goldman Sachs just told you what to buy (most people missed it) (Ad)

Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up.

One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.

See the stock positioned to solve AI's biggest power crisis

Clearly, this is a positive, as it should increase demand for Lilly’s products. It also weakens Lilly’s biggest competitor, since CVS is backing away from its previous move to exclude Lilly from coverage.

CVS Reunites With Lilly After Backing Novo

With this announcement, all three of the United States' largest PBMs will soon cover Lilly’s entire portfolio of approved obesity medications. Express Scripts, owned by Cigna Group (NYSE: CI), and Optum Rx, owned by UnitedHealth Group (NYSE: UNH), already covered the drugs. Caremark will begin covering Foundayo on June 1, while coverage for Zepbound will begin on Oct. 1.

What makes this announcement particularly interesting is the context. Just over a year ago, CVS struck a deal with Lilly’s main competitor, Novo Nordisk A/S (NYSE: NVO). That made Novo’s Wegovy CVS’s preferred GLP-1 treatment and excluded Zepbound from coverage. Combined with its slightly disappointing earnings report on May 1, 2025, this move between Lilly’s top rival and the largest PBM sent LLY shares down almost 12%.

Now, CVS has reversed that decision, which had delivered a real blow to Lilly shares. According to a CVS spokesperson, “What this change means is that, for those clients that do (choose to provide coverage), they will have equal access to both the Novo and Lilly products, and consumers will have the same co-pays for each.” In other words, if an employer covers GLP-1s for obesity, their employees can access Novo and Lilly’s products equally and at the same co-pay.

This should largely reverse the negative effect of CVS’s initial decision, which limited access to Lilly’s drugs and hurt demand. It also removes the advantage Novo had as the only available option for CVS clients.

Timing is another positive aspect of this decision, as Lilly is looking to boost demand for Foundayo. Its oral GLP-1 has fallen behind Novo’s Wegovy pill, which received FDA approval several months earlier. Now that it is on equal footing with Novo within Caremark, Lilly may have an easier time catching up. Lilly shares gained 4% on the day of the announcement as investors reacted to the positive implications for the company.

Zooming in on Valuation Amid Lilly’s Rebound

Despite the many positive developments Lilly has seen in late 2026, the stock has underperformed overall. Shares are down about 1% compared with the S&P 500’s gain of more than 10%. This comes after its latest earnings report helped kick off a recovery—before that release, shares were down nearly 21% in 2026. Now, Lilly trades less than 5% below its all-time high. Given that backdrop, it is worth examining the stock’s valuation for a more complete view of the outlook for LLY shares.

Currently, the stock trades at a forward price-to-earnings (P/E) ratio near 29x. That is well above the S&P 500’s forward P/E near 21x, and even further above the S&P 500 healthcare sector’s forward P/E near 17x. Based on these measures, Lilly’s valuation looks fairly elevated.

However, compared with Lilly’s own history, that is not the case. Over the past three years, Lilly’s average forward P/E is nearly 43x. So its current level is about 33% below that average, which is a much more favorable comparison. Over the past 52 weeks, Lilly’s average forward P/E is around 30x, just slightly above its current level.

Lilly’s forward P/E has also come down meaningfully from 32x, when the stock traded near its current price in February. This suggests that earnings estimates have caught up with the stock price somewhat, which is a positive sign. Overall, Lilly is certainly not a cheap stock, and it will need to keep delivering strong growth to support its valuation. However, these metrics show that it is also not a name that necessarily screams "overvalued."

Analysts Remain Constructive on Lilly’s Upside Potential

The outlook for Lilly shares, according to Wall Street analyst price targets, remains positive. The MarketBeat consensus price target on the stock currently sits near $1,227, implying about 15% upside.

The average of targets updated after the company’s earnings report is modestly higher at $1,239.

Among these updates, Rothschild & Co Redburn’s $900 target is the most bearish. Meanwhile, Barclays’ $1,400 target is the most bullish.